Developer docs
API playgroundTry for free, no card

Search company profiles

Aisling Capital

Full company profile

uuid00007s8

Namestring
Aisling Capital
Legal namestring
Aisling Capital Management LP
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 by Dennis Purcell. The firm manages over $1.8 billion in committed capital across four to five funds, deploying capital into biopharmaceuticals, medical devices, diagnostics, and healthcare services companies via seed and venture financings, small-cap public equities, structured debt and royalty deals, and leveraged buyouts. Its investment team of 8+ professionals combines 150+ years of healthcare industry experience across clinical, operational, and financial disciplines, supplemented by three MD-level Operating Partners who have served as executives and board members of portfolio companies including Loxo Oncology and Marinus Pharmaceuticals.

The firm's portfolio spans development-stage and public companies across multiple therapeutic modalities, including oncology (BridgeBio Oncology Therapeutics, Bicara Therapeutics, Monte Rosa Therapeutics), psychedelic medicine (COMPASS Pathways), gene therapy manufacturing (Forge Biologics), and stem cell technology (Garuda Therapeutics). Notable exits include Loxo Oncology's acquisition by Eli Lilly for approximately $8 billion and ZELTIQ's acquisition by Allergan for approximately $2.4 billion. Aisling generates revenue through conventional fund management economics: management fees on committed capital and carried interest on investment profits, distributed to more than 90 institutional limited partners including pension funds, endowments, and family offices. The firm maintains a single headquarters at 489 5th Avenue in New York and is registered as an investment adviser (Aisling Capital Management LP) with the U.S. Securities and Exchange Commission.

Short descriptiontext

Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 that manages over $1.8 billion across multiple funds, investing in biopharmaceutical, medical device, diagnostics, and healthcare services companies and serving more than 90 institutional limited partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, life sciences investment, biopharmaceutical financing, private equity healthcare, growth equity investments
Industry1 code
PRIMARYFSANAAAL
Venture Debt Providers
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management
TypeSubscription Recurring
Description

Aisling Capital generates returns through management fees on committed capital and carried interest on investment profits. The firm has raised over $1.8 billion across multiple funds since 2000, investing in development-stage companies, public equities, structured debt, and buyouts across the life sciences industry.

aislingcapital.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aisling Capital is a private investment firm that manages committed capital across multiple funds and deploys it into healthcare and life sciences companies. The firm invests in biopharmaceutical, medical device, diagnostics, and healthcare services businesses through seed and venture financings, small-cap public equities, structured debt and royalty deals, and large-cap leveraged buyouts, while providing active strategic guidance to portfolio company management teams.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Multiple successful portfolio company exits including Loxo Oncology acquired by Eli Lilly for approximately $8 billion, ZELTIQ acquired by Allergan for approximately $2.4 billion, and numerous other acquisitions
Product overview1 text field

Aisling Capital is a healthcare investment firm that invests in companies developing and commercializing innovative healthcare products, services, and technologies. The firm does not offer a single unified product or platform; rather, it manages a diversified portfolio of biopharmaceutical, biotechnology, medical device, diagnostics, and healthcare services companies. As an investment management entity, Aisling Capital's offerings consist of investment funds and strategic guidance to portfolio companies rather than standalone software products or services.

Product and service2 records
1Aisling Capital Healthcare Investment Funds
CategoryInvestment Management
2Strategic Guidance and Active Portfolio Engagement
CategoryPortfolio Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage healthcare and biotech venture firm building companies from inception. Comparable in clinical-credentialed team and focus on formation-stage biotech investing.

TypeDirect peer
Description

Healthcare-focused venture and growth firm investing in biopharma and medical devices. Comparable in therapeutic-area breadth and stage-spanning strategy within healthcare.

TypeDirect peer
Description

Healthcare-dedicated investment firm managing ~$17B across venture, growth, and public equity strategies. Directly comparable to Aisling given its stage-spanning healthcare investing approach and clinical-scientific team orientation.

TypeDirect peer
Description

Healthcare-focused investment firm with venture, growth, and structured credit capabilities, managing ~$15B. Comparable to Aisling as a multi-strategy healthcare investor participating in similar rounds (e.g., co-investor in CalciMedica).

TypeDirect peer
Description

Healthcare/biotech-focused hedge fund and private investor that frequently co-invests with Aisling (e.g., BBOT financing). Comparable as a healthcare specialist deploying capital across stages with deep biotech networks.

TypeDirect peer
Description

Healthcare-focused investment firm investing across private and public healthcare companies. Co-led the BBOT financing alongside Cormorant with Aisling participating, reflecting direct co-investment overlap.

TypeDirect peer
Description

Healthcare-focused crossover fund investing across public and private life sciences companies. Comparable stage-spanning strategy and clinical diligence approach as Aisling.

8Baker Bros. Advisors
TypeDirect peer
Description

Healthcare/biotech-focused long-only adviser founded by brothers with PhDs, managing multi-billion AUM. Comparable clinical-scientific orientation and concentrated life sciences investment mandate.

TypeDirect peer
Description

Healthcare-dedicated venture and growth equity firm with $4B+ AUM. Comparable in stage-spanning healthcare focus and operating-partner-style support for portfolio companies.

TypeDirect peer
Description

Healthcare-dedicated investment firm co-leading rounds like Bicara Therapeutics' $165M Series C with Aisling participating. Directly comparable as a healthcare-focused investor in similar therapeutic areas.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment185 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aisling Capital

Healthcare Venture Capitalaislingcapital.com

Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 that manages over $1.8 billion across multiple funds, investing in biopharmaceutical, medical device, diagnostics, and healthcare services companies and serving more than 90 institutional limited partners.

What Aisling Capital does

Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 by Dennis Purcell. The firm manages over $1.8 billion in committed capital across four to five funds, deploying capital into biopharmaceuticals, medical devices, diagnostics, and healthcare services companies via seed and venture financings, small-cap public equities, structured debt and royalty deals, and leveraged buyouts. Its investment team of 8+ professionals combines 150+ years of healthcare industry experience across clinical, operational, and financial disciplines, supplemented by three MD-level Operating Partners who have served as executives and board members of portfolio companies including Loxo Oncology and Marinus Pharmaceuticals.

The firm's portfolio spans development-stage and public companies across multiple therapeutic modalities, including oncology (BridgeBio Oncology Therapeutics, Bicara Therapeutics, Monte Rosa Therapeutics), psychedelic medicine (COMPASS Pathways), gene therapy manufacturing (Forge Biologics), and stem cell technology (Garuda Therapeutics). Notable exits include Loxo Oncology's acquisition by Eli Lilly for approximately $8 billion and ZELTIQ's acquisition by Allergan for approximately $2.4 billion. Aisling generates revenue through conventional fund management economics: management fees on committed capital and carried interest on investment profits, distributed to more than 90 institutional limited partners including pension funds, endowments, and family offices. The firm maintains a single headquarters at 489 5th Avenue in New York and is registered as an investment adviser (Aisling Capital Management LP) with the U.S. Securities and Exchange Commission.

Aisling Capital firmographics

Firmographics
Name
Aisling Capital
Legal name
Aisling Capital Management LP
Website
https://aislingcapital.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Aisling Capital is a New York-based healthcare-focused venture capital and private equity firm founded in 2000 that manages over $1.8 billion across multiple funds, investing in biopharmaceutical, medical device, diagnostics, and healthcare services companies and serving more than 90 institutional limited partners.
Ownership category
akta.pro rank

Aisling Capital industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAL
Venture Debt Providers

Keywords

  • Healthcare venture capital
  • Life sciences investment
  • Biopharmaceutical financing
  • Private equity healthcare
  • Growth equity investments

Where Aisling Capital is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aisling Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Investment Management: Aisling Capital generates returns through management fees on committed capital and carried interest on investment profits. The firm has raised over $1.8 billion across multiple funds since 2000, investing in development-stage companies, public equities, structured debt, and buyouts across the life sciences industry.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Aisling Capital product offering

Product offering

Core offering

Aisling Capital is a private investment firm that manages committed capital across multiple funds and deploys it into healthcare and life sciences companies. The firm invests in biopharmaceutical, medical device, diagnostics, and healthcare services businesses through seed and venture financings, small-cap public equities, structured debt and royalty deals, and large-cap leveraged buyouts, while providing active strategic guidance to portfolio company management teams.

Product overview

Aisling Capital is a healthcare investment firm that invests in companies developing and commercializing innovative healthcare products, services, and technologies. The firm does not offer a single unified product or platform; rather, it manages a diversified portfolio of biopharmaceutical, biotechnology, medical device, diagnostics, and healthcare services companies. As an investment management entity, Aisling Capital's offerings consist of investment funds and strategic guidance to portfolio companies rather than standalone software products or services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aisling Capital Healthcare Investment Funds
  • Strategic Guidance and Active Portfolio Engagement

Quantifiable outcome

  • Multiple successful portfolio company exits including Loxo Oncology acquired by Eli Lilly for approximately $8 billion, ZELTIQ acquired by Allergan for approximately $2.4 billion, and numerous other acquisitions

Companies that use Aisling Capital

Customer profile

Segments1 record

Ideal customer profiles2 records

Aisling Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aisling Capital partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Aisling Capital competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Early-stage healthcare and biotech venture firm building companies from inception. Comparable in clinical-credentialed team and focus on formation-stage biotech investing.
  • New Leaf Venture Partners: Healthcare-focused venture and growth firm investing in biopharma and medical devices. Comparable in therapeutic-area breadth and stage-spanning strategy within healthcare.
  • OrbiMed Advisors: Healthcare-dedicated investment firm managing ~$17B across venture, growth, and public equity strategies. Directly comparable to Aisling given its stage-spanning healthcare investing approach and clinical-scientific team orientation.
  • Deerfield Management: Healthcare-focused investment firm with venture, growth, and structured credit capabilities, managing ~$15B. Comparable to Aisling as a multi-strategy healthcare investor participating in similar rounds (e.g., co-investor in CalciMedica).
  • Cormorant Asset Management: Healthcare/biotech-focused hedge fund and private investor that frequently co-invests with Aisling (e.g., BBOT financing). Comparable as a healthcare specialist deploying capital across stages with deep biotech networks.
  • Omega Funds: Healthcare-focused investment firm investing across private and public healthcare companies. Co-led the BBOT financing alongside Cormorant with Aisling participating, reflecting direct co-investment overlap.
  • RA Capital Management: Healthcare-focused crossover fund investing across public and private life sciences companies. Comparable stage-spanning strategy and clinical diligence approach as Aisling.
  • Baker Bros. Advisors: Healthcare/biotech-focused long-only adviser founded by brothers with PhDs, managing multi-billion AUM. Comparable clinical-scientific orientation and concentrated life sciences investment mandate.
  • Frazier Healthcare Partners: Healthcare-dedicated venture and growth equity firm with $4B+ AUM. Comparable in stage-spanning healthcare focus and operating-partner-style support for portfolio companies.
  • Braidwell LP: Healthcare-dedicated investment firm co-leading rounds like Bicara Therapeutics' $165M Series C with Aisling participating. Directly comparable as a healthcare-focused investor in similar therapeutic areas.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Aisling Capital social profiles

Digital presence

Aisling Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aisling Capital leadership team

Management profile

Number of profiles

Profiles13 records

Aisling Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aisling Capital M&A and investment

M&A and investment

M&A

Investments185 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aisling Capital

What does Aisling Capital do?

Aisling Capital is a private investment firm that manages committed capital across multiple funds and deploys it into healthcare and life sciences companies. The firm invests in biopharmaceutical, medical device, diagnostics, and healthcare services businesses through seed and venture financings, small-cap public equities, structured debt and royalty deals, and large-cap leveraged buyouts, while providing active strategic guidance to portfolio company management teams.

Is Aisling Capital a public or private company?

Aisling Capital is a private company. It is classified as management employee owned and is currently operating.

When was Aisling Capital founded?

Aisling Capital was founded in 2000. It employs 11 to 50 people.

Where is Aisling Capital based?

Aisling Capital is headquartered in New York, United States, in the North America region.

How does Aisling Capital make money?

One revenue line is on record: investment Management.

Who are Aisling Capital's main competitors?

Direct peers on record are Atlas Venture, New Leaf Venture Partners, OrbiMed Advisors, Deerfield Management, Cormorant Asset Management, Omega Funds, RA Capital Management, Baker Bros. Advisors, Frazier Healthcare Partners and Braidwell LP.

Does Aisling Capital have an API?

No public API is recorded for Aisling Capital.

What industry is Aisling Capital in?

Aisling Capital's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsClaris Biotherapeutics Raises $118M in Series B FundingClaris Biotherapeutics raised $118M in Series B financing led by Samsara Biocapital and Catalio Capital Management. The funds will complete clinical trials for CSB-001 in limbal stem cell deficiency and support a planned 2027 pivotal program. The company also aims to enable pre-commercialization activities.Venture Capital Access OnlineClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.BioSpaceClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.GlobeNewswireCOMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare InvestorsCOMPASS Pathways announced a private placement financing of up to $285 million, led by TCGX and Aisling Capital, with $125 million upfront and up to $160 million from warrant exercise. The financing is expected to close August 18, 2023, and net proceeds will fund its pivotal phase 3 program in treatment-resistant depression and other trials.GlobeNewswireCOMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare InvestorsCOMPASS Pathways announced a private placement of 16,076,750 ADSs and warrants, led by TCGX and Aisling Capital, for up to $285 million. The financing, expected to close August 18, 2023, will fund its phase 3 trial in treatment-resistant depression and extend cash runway into late 2025.Pulse 2.0Blood Stem Cell-Based Cellular Therapy Company Garuda Therapeutics Raises $62 MillionGaruda Therapeutics raised $62 million in a Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital, bringing total funding to $134 million. The company will use the proceeds to advance its off-the-shelf blood stem cell platform for hematological and oncologic diseases.FinSMEsGaruda Therapeutics Raises $62M in Series B FinancingGaruda Therapeutics raised $62 million in Series B funding, bringing its total capitalization to $134 million. The round was led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital, with participation from other investors. The company intends to use the funds to advance the clinical development of its off-the-shelf blood stem cell therapies for hematological diseases and oncologic disorders.VC News DailyGaruda Therapeutics Scoops Up $62M Series BGaruda Therapeutics announced the closing of a $62 million Series B financing round led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital. This investment brings the company's total funding to $134 million and includes the appointment of Raymond J. Kelleher to its Board of Directors. The capital will support Garuda's development of off-the-shelf blood stem cell-based cellular therapies.American City Business JournalsGene therapy startup Forge Biologics raises $90M on biotech manufacturing strengthForge Biologics raised $90 million in a Series C round led by Drive Capital and Aisling Capital, bringing cumulative funding to $330 million. The Grove City, Ohio-based gene therapy manufacturer is expanding its 200,000-square-foot cleanroom facility and has 255 employees. The company aims to start commercial production in 2023.FinSMEsGaruda Therapeutics Raises $72M in Series A FinancingGaruda Therapeutics raised $72 million in Series A financing led by Aisling Capital, Northpond Ventures, and Orbimed. The company develops off-the-shelf blood stem cell therapies, with a pipeline targeting over 70 diseases including hematologic malignancies and sickle cell disease.